Rima K. Acosta

发表

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

H. Stellbrink, P. Sax, H. Albrecht, 2019, The lancet. HIV.

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

K. White, Ross Martin, D. SenGupta, 2019, Antimicrobial Agents and Chemotherapy.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro

K. White, S. Yant, T. Cihlar, 2022, Antimicrobial agents and chemotherapy.

Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.

K. White, S. Yant, T. Cihlar, 2020, Journal of acquired immune deficiency syndromes.

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

D. Podzamczer, H. Stellbrink, P. Sax, 2020, The lancet. HIV.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

K. White, Ross Martin, Hal Martin, 2021, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.

K. White, Ross Martin, Hal Martin, 2020, Journal of acquired immune deficiency syndromes.

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

D. Ward, P. Sax, Y. Yazdanpanah, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Y. Yazdanpanah, A. Antinori, A. Clarke, 2019, The lancet. HIV.

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.

K. White, A. Thielen, Ross Martin, 2018, Journal of acquired immune deficiency syndromes.

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.

K. White, D. Brainard, Ross Martin, 2021, The Journal of antimicrobial chemotherapy.

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance

K. White, S. Yant, T. Cihlar, 2020 .

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

J. Baeten, H. Stellbrink, P. Sax, 2023, EClinicalMedicine.

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.

C. Kityo, V. Pokrovsky, A. Avihingsanon, 2019, Journal of acquired immune deficiency syndromes.